From Ganfyd

Jump to: navigation, search

Erenumab is a anti-CGRP monoclonal antibody that blocks the calcitonin gene-related peptide (CGRP) receptor which is a heterodimer of calcitonin gene-related peptide type 1 receptor and its transport protein receptor activity-modifying protein 1. It is in advanced development for the treatment of migraine[1][2] with phase 3 trials complete. It is likely the dose will be 70mg monthly subcutaneously with the expectation that 50% of sufferers will achieve a 50% reduction in headache frequency.